SCHEMBL97324

SCHEMBL97324

[CH2]CCCCO[Si](C)(C)C(C)(C)C

nearest known ligand 0.38

Predicted protein targets (top 1)

geneUniProtsupporting neighboursconfidence
DUT P33316 2/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9517441 0.98 DUT (0.37) DUT
SCHEMBL97731 0.98 DUT (0.37) DUT
SCHEMBL9517422 0.98 DUT (0.37) DUT
SCHEMBL94712 0.93 DUT (0.39) DUT
SCHEMBL8063404 0.88 DUT (0.43) DUT
SCHEMBL9007756 0.85 DUT (0.42) DUT
SCHEMBL14245094 0.85 DUT (0.42) DUT
SCHEMBL27241092 0.85 DUT (0.42) DUT
SCHEMBL95573 0.83 DUT (0.34) DUT
SCHEMBL28000694 0.81 DUT (0.33) DUT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-107954933-B 2-azabicyclo [4.2.0] octane compounds and synthesis and application thereof 浙江大学 2020-10-23 CN claimed
CN-114245798-A CGRP antagonist compounds 赫普泰雅治疗有限公司 2022-03-25 CN disclosed
CN-107954933-B 2-azabicyclo [4.2.0] octane compounds and synthesis and application thereof 浙江大学 2020-10-23 CN disclosed
US-8362252-B2 Carbostyril compound OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2013-01-29 US disclosed
EP-1797082-B1 CARBOSTYRIL COMPOUND OTSUKA PHARMA CO LTD (JP) 2012-08-29 EP disclosed
EP-2426128-A1 Carbostyril compound Otsuka Pharmaceutical Co., Limited (JP) 2012-03-07 EP disclosed
US-20100261705-A1 CARBOSTYRIL COMPOUND OTSUKA PHARMACEUTICAL CO., LTD. 2010-10-14 US disclosed
US-7777038-B2 Carbostyril compound OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2010-08-17 US disclosed
US-7723514-B2 Method of preparing a 5H-dibenz(b,f)azepine-5-carboxamide TARO PHARMACEUTICALS U.S.A., INC. (US) 2010-05-25 US disclosed
US-20090326008-A1 NF-kappa B Inhibitor OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2009-12-31 US disclosed
US-20060241292-A1 Method of preparing a 5H-dibenz(b,f)azepine-5-carboxamide TARO PHARMACEUTICALS USA, INC (US) 2006-10-26 US disclosed
US-7091339-B2 Method of preparing a 5H-dibenz(b,f)azepine-5-carboxamide TARO PHARMACEUTICALS USA, INC. (US) 2006-08-15 US disclosed
WO-2006035954-A1 CARBOSTYRIL COMPOUND OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2006-04-06 WO disclosed
EP-1482924-A4 CATHEPSIN CYSTEINE PROTEASE INHIBITORS MERCK FROSST CANADA INC (CA) 2006-03-08 EP disclosed
EP-1513816-A2 METHOD OF PREPARING A 5H-DIBENZ(B,F)AZEPINE-5-CARBOXAMIDE TARO PHARMACEUTICALS U.S.A., INC. (US) 2005-03-16 EP disclosed
EP-1482924-A2 CATHEPSIN CYSTEINE PROTEASE INHIBITORS MERCK FROSST CANADA INC. (CA) 2004-12-08 EP disclosed
US-20040044200-A1 Method of preparing a 5H-dibenz(b,f)azepine-5-carboxamide TARO PHARMACEUTICALS U.S.A. 2004-03-04 US disclosed
WO-2003106414-A2 METHOD OF PREPARING A 5H-DIBENZ[B,F]AZEPINE-5-CARBOXAMIDE TARO PHARMACEUTICALS U.S.A., INC. (US) 2003-12-24 WO disclosed
WO-2003075836-A2 CATHEPSIN CYSTEINE PROTEASE INHIBITORS MERCK FROSST CANADA & CO. (CA) 2003-09-18 WO disclosed
EP-0140307-A2 7-Oxabicycloheptane ethers E.R. Squibb & Sons, Inc. (US) 1985-05-08 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090326008-A1 NF-kappa B Inhibitor NFKBIA, NFKB2, IKBKB DUT 4147/4885
US-20040044200-A1 Method of preparing a 5H-dibenz(b,f)azepine-5-carboxamide KCNH1, KCNMB1, KCNMB4 DUT 447/4885
US-20060241292-A1 Method of preparing a 5H-dibenz(b,f)azepine-5-carboxamide C5, C1S, CBR3 DUT 482/4885
US-20100261705-A1 CARBOSTYRIL COMPOUND GTF2F1, F3, GTF2F2 DUT 4729/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.